Switch to:
Onyx Pharmaceuticals, Inc. (NAS:ONXX)
Piotroski F-Score
0 (As of Today)

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Onyx Pharmaceuticals, Inc. has an F-score of 3 indicating the company's financial situation is typical for a stable company.

ONXX' s 10-Year Piotroski F-Score Range
Min: 0   Max: 0
Current: 0


Definition

How is the Piotroski F-Score calculated?

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

This Year (Jun13) TTM:Last Year (Jun12) TTM:
Net Income was 17.396 + -42.921 + -33.671 + -53.168 = $-112.4 Mil.
Cash Flow from Operations was -42.509 + -100.993 + -111.173 + -3.351 = $-258.0 Mil.
Revenue was 89.511 + 127.919 + 145.492 + 153.026 = $515.9 Mil.
Gross Profit was 89.015 + 127.087 + 143.524 + 150.983 = $510.6 Mil.
Average Total Assets from the begining of this year (Jun12)
to the end of this year (Jun13) was
(1365.197 + 1376.363 + 1351.571 + 1677.318 + 1679.242) / 5 = $1,489.9 Mil.
Total Assets was $1,679.2 Mil.
Long-Term Debt was $180.7 Mil.
Total Current Assets was $1,021.7 Mil.
Total Current Liabilities was $122.4 Mil.
Net Income was -36.86 + 216.675 + -56.212 + -106.049 = $17.6 Mil.

Revenue was 75.041 + 237.032 + 72.031 + 72.704 = $456.8 Mil.
Gross Profit was 75.041 + 237.032 + 72.031 + 72.704 = $456.8 Mil.
Average Total Assets from the begining of last year (Jun11)
to the end of last year (Jun12) was
(1285.442 + 1270.936 + 1411.724 + 1380.804 + 1365.197) / 5 = $1,342.8 Mil.
Total Assets was $1,365.2 Mil.
Long-Term Debt was $168.5 Mil.
Total Current Assets was $660.1 Mil.
Total Current Liabilities was $152.1 Mil.

Profitability

Q1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by average total assets throughout the year.

Score 1 if positive, 0 if negative.

Onyx Pharmaceuticals, Inc.'s current net income (ttm) was -112.4. ==> Negative ==> Score 0.

Q2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by average total assets throughout the year.

Score 1 if positive, 0 if negative.

Onyx Pharmaceuticals, Inc.'s current cash flow from operations (ttm) was -258.0. ==> Negative ==> Score 0.

Q3. Change in Return on Assets

Compare this year’s return on assets (1) to last year’s return on assets.

Score 1 if it’s higher, 0 if it’s lower.

ROA (This Year)=Net Income (TTM)/Average Total Assets from Jun12 to Jun13
=-112.364/1489.9382
=-0.07541521

ROA (Last Year)=Net Income (TTM)/Average Total Assets from Jun11 to Jun12
=17.554/1342.8206
=0.01307248

Onyx Pharmaceuticals, Inc.'s return on assets of this year was -0.07541521. Onyx Pharmaceuticals, Inc.'s return on assets of last year was 0.01307248. ==> Last year is higher ==> Score 0.

Q4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA =< ROA.

Onyx Pharmaceuticals, Inc.'s current net income (ttm) was -112.4. Onyx Pharmaceuticals, Inc.'s current cash flow from operations (ttm) was -258.0. ==> -258.0 =< -112.4 ==> CFROA =< ROA ==> Score 0.

Funding

Q5. Change in Gearing or Leverage

Compare this year’s gearing (long-term debt divided by total assets) to last year’s gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun13)=Long-Term Debt/Total Assets
=180.7/1679.242
=0.10760808

Gearing (Last Year: Jun12)=Long-Term Debt/Total Assets
=168.474/1365.197
=0.12340637

Onyx Pharmaceuticals, Inc.'s gearing of this year was 0.10760808. Onyx Pharmaceuticals, Inc.'s gearing of last year was 0.12340637. ==> This year is lower or equal to last year. ==> Score 1.

Q6. Change in Working Capital (Liquidity)

Compare this year’s current ratio (current assets divided by current liabilities) to last year’s current ratio.

Score 1 if this year'’s current ratio is higher, 0 if it’s lower

Current Ratio (This Year: Jun13)=Total Current Assets/Total Current Liabilities
=1021.725/122.351
=8.35076951

Current Ratio (Last Year: Jun12)=Total Current Assets/Total Current Liabilities
=660.062/152.138
=4.33857419

Onyx Pharmaceuticals, Inc.'s current ratio of this year was 8.35076951. Onyx Pharmaceuticals, Inc.'s current ratio of last year was 4.33857419. ==> This year's current ratio is higher. ==> Score 1.

Q7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Onyx Pharmaceuticals, Inc.'s number of shares in issue this year was 73. Onyx Pharmaceuticals, Inc.'s number of shares in issue last year was 64.2. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Q8. Change in Gross Margin

Compare this year’s gross margin (gross profit divided by sales) to last year’s.

Score 1 if this year’s gross margin is higher, 0 if it’s lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=510.609/515.948
=0.98965206

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=456.808/456.808
=1

Onyx Pharmaceuticals, Inc.'s gross margin of this year was 0.98965206. Onyx Pharmaceuticals, Inc.'s gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Q9. Change in asset turnover

Compare this year’s asset turnover (total sales for the year divided by average total assets throughout the year) to last year’s asset turnover ratio.

Score 1 if this year’s asset turnover ratio is higher, 0 if it’s lower

Asset Turnover (This Year)=Revenue (TTM)/Average Total Assets from Jun12 to Jun13
=515.948/1489.9382
=0.34628819

Asset Turnover (Last Year)=Revenue (TTM)/Average Total Assets from Jun11 to Jun12
=456.808/1342.8206
=0.34018543

Onyx Pharmaceuticals, Inc.'s asset turnover of this year was 0.34628819. Onyx Pharmaceuticals, Inc.'s asset turnover of last year was 0.34018543. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score=Q1+Q2+Q3+Q4+Q5+Q6+Q7+Q8+Q9
=0+0+0+0+1+1+0+0+1
=3

Good or high score = 8 or 9

Bad or low score = 0 or 1

Onyx Pharmaceuticals, Inc. has an F-score of 3 indicating the company's financial situation is typical for a stable company.


Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Related Terms

Net Income, Cash Flow from Operations, Revenue, Gross Profit, Total Assets, Long-Term Debt, Total Current Assets, Total Current Liabilities, Altman Z-Score, Beneish M-Score


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Onyx Pharmaceuticals, Inc. Annual Data

Dec03Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12
Q1 0000011010
Q2 0000001110
Q3 1100111010
Q4 1010101100
Q5 1111110000
Q6 1101100100
Q7 0000000000
Q8 0000000000
Q9 0110111110
F-score 4432545440

Onyx Pharmaceuticals, Inc. Quarterly Data

Mar11Jun11Sep11Dec11Mar12Jun12Sep12Dec12Mar13Jun13
Q1 0001111000
Q2 0001111000
Q3 0101111000
Q4 1110010000
Q5 0000001011
Q6 1110000011
Q7 0000000000
Q8 0000000000
Q9 0001111001
F-score 2324455023
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK